View More Recent Stories
-
Praxis Precision Medicines (PRAX) spreader active in November 65 and 90 calls as share price up 9.6%
-
Truist Securities Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $151 at Needham
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $143 at Oppenheimer
-
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Guggenheim Defending Praxis Precision Medicines Inc. (PRAX): 'we are buyers, especially on the current weakness'
-
Truist Securities Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Truist Securities Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines (PRAX) announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $120 at H.C. Wainwright
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $170 at Guggenheim
-
Oppenheimer Starts Praxis Precision Medicines Inc. (PRAX) at Outperform
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)

